Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
- Humby, Frances
- Lewis, Myles
- Ramamoorthi, Nandhini
- Hackney, Jason A.
- Barnes, Michael R.
- Bombardieri, Michele
- Setiadi, A. Francesca
- Kelly, Stephen
- Bene, Fabiola
- DiCicco, Maria
- Riahi, Sudeh
- Rocher, Vidalba
- Ng, Nora
- Lazarou, Ilias
- Hands, Rebecca
- van der Heijde, Désirée
- Landewé, Robert B. M.
- van der Helm-van Mil, Annette
- Cauli, Alberto
- McInnes, Iain
- Buckley, Christopher Dominic
- Choy, Ernest H.
- Taylor, Peter C.
- Townsend, Michael J.
- Pitzalis, Costantino
DOIAbstract
Objectives To unravel the hierarchy of cellular/molecular pathways in the disease tissue of early, treatment-naïve rheumatoid arthritis (RA) patients and determine their relationship with clinical phenotypes and treatment response/outcomes longitudinally. Methods 144 consecutive treatment-naïve early RA patients (<12 months symptoms duration) underwent ultrasound-guided synovial biopsy before and 6 months after disease-modifying antirheumatic drug (DMARD) initiation. Synovial biopsies were analysed for cellular (immunohistology) and molecular (NanoString) characteristics and results compared with clinical and imaging outcomes. Differential gene expression analysis and logistic regression were applied to define variables correlating with tre...
Add to ORKG